DUBLIN--(BUSINESS WIRE)--The "Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017 provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 6, 5, 18 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively.
Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Influenza A Virus, H3N2 Subtype Infections - Overview
- Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
- AbbVie Inc
- Adimmune Corp
- AIMM Therapeutics BV
- Aphios Corp
- BioCryst Pharmaceuticals Inc
- BiondVax Pharmaceuticals Ltd
- Cadila Healthcare Ltd
- Celltrion Inc
- FluGen Inc
- Glide Pharmaceutical Technologies Ltd
- Inovio Pharmaceuticals Inc
- Jiangsu Kanion Pharmaceutical Co Ltd
- Johnson & Johnson
- Medicago Inc
- MedImmune LLC
- Mucosis BV
- NanoViricides Inc
- Novavax Inc
- OPKO Health Inc
- Protein Sciences Corp
- Sanofi Pasteur SA
- Sarepta Therapeutics Inc
- SK Chemicals Co Ltd
- Takeda Pharmaceutical Company Ltd
- VBI Vaccines Inc
- Visterra Inc
For more information about this report visit https://www.researchandmarkets.com/research/f2kvdd/influenza_a
